Nuclear Diagnostics Target IRE and its subsidiary IRE ELiT for radiopharmaceuticals and diagnostic radiotracers, highlighting potential upsell of advanced imaging isotopes, quality control services, and compliance consulting to expand their diagnostic capabilities.

Cancer Therapies Position radiopharmaceutical derivatives used in cancer treatment as a growth area; offer expanded production, customization, and regulatory support for new cancer radiopharmaceuticals and companion diagnostic workflows.

Radiological Monitoring Leverage IRE ELiT's radiological monitoring lab to propose data analytics, monitoring software, and remote sensing solutions; provide services around radiological characterization, data integration, and project development in international radiology initiatives.

Public Utility Advantage Emphasize the public utility foundation status to explore long-term, stable partnerships, grant-backed R&D collaborations, and potential access to government or European funding for nuclear medicine initiatives.

Tech Enablement Align technology stack capabilities with procurement of advanced IT and data infrastructure services, such as scalable databases, analytics, and security upgrades, to support production of isotopes and regulatory reporting.